Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.67 |
| ▸ | MAPT | P10636 | 5/20 | 0.67 |
| ▸ | LMNA | P02545 | 3/20 | 0.67 |
| ▸ | KCNJ1 | P48048 | 2/20 | 0.67 |
| ▸ | PKM | P14618 | 2/20 | 0.65 |
| ▸ | RIPK1 | Q13546 | 4/20 | 0.55 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.51 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | NPBWR1 | P48145 | 2/20 | 0.50 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.50 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7350400 | 0.91 | KDM4E (0.54) | KDM4EALDH1A1MAPTLMNAKCNJ1 | |
| SCHEMBL28307941 | 0.88 | KDM4E (0.68) | KDM4EALDH1A1MAPTLMNAKCNJ1 | |
| SCHEMBL28291116 | 0.87 | KDM4E (0.63) | KDM4EALDH1A1MAPTLMNAKCNJ1 | |
| SCHEMBL16197999 | 0.85 | MAPT (0.73) | KDM4EALDH1A1MAPTLMNAKCNJ1 | |
| SCHEMBL28291150 | 0.85 | KDM4E (0.66) | KDM4EALDH1A1MAPTLMNAKCNJ1 | |
| SCHEMBL8601357 | 0.81 | KDM4E (1.00) | KDM4EALDH1A1MAPTLMNAKCNJ1 | |
| SCHEMBL9642133 | 0.81 | MAPT (1.00) | KDM4EALDH1A1MAPTLMNAKCNJ1 | |
| SCHEMBL2145376 | 0.80 | KCNJ1 (0.80) | KDM4EALDH1A1MAPTLMNAKCNJ1 | |
| SCHEMBL7033535 | 0.79 | MAPT (0.91) | KDM4EALDH1A1MAPTLMNAKCNJ1 | |
| SCHEMBL28307940 | 0.79 | MAPT (0.63) | KDM4EALDH1A1MAPTLMNAKCNJ1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109988794-B | Method for synthesizing nitrobenzimidazole derivatives through enzyme catalysis in continuous flow reactor | 浙江农林大学 | 2023-06-13 | — | — | CN | disclosed |
| CN-109988794-A | A method of the Enzyme catalyzed synthesis nitrobenzimidazole analog derivative in continuous flow reactor | 浙江农林大学 | 2019-07-09 | — | — | CN | disclosed |
| US-9643933-B2 | Compounds useful as antibiotic tolerance inhibitors | THE GENERAL HOSPITAL CORPORATION (US) | 2017-05-09 | — | — | US | disclosed |
| US-9643933-B2 | Compounds useful as antibiotic tolerance inhibitors | THE GENERAL HOSPITAL CORPORATION (US) | 2017-05-09 | — | — | US | disclosed |
| US-20160052890-A1 | COMPOUNDS USEFUL AS ANTIBIOTIC TOLERANCE INHIBITORS | THE GENERAL HOSPITAL CORPORATION (US) | 2016-02-25 | — | — | US | disclosed |
| US-20160052890-A1 | COMPOUNDS USEFUL AS ANTIBIOTIC TOLERANCE INHIBITORS | THE GENERAL HOSPITAL CORPORATION (US) | 2016-02-25 | — | — | US | disclosed |
| WO-2014176258-A1 | COMPOUNDS USEFUL AS ANTIBIOTIC TOLERANCE INHIBITORS | THE GENERAL HOSPITAL CORPORATION (US) | 2014-10-30 | — | — | WO | disclosed |
| US-5741804-A | Substituted benzimazoles which inhibit platelet aggrecation | SMITHKLINE BEECHAM CORPORATION (US) | 1998-04-21 | — | — | US | disclosed |
| EP-0672034-A4 | BENZIMIDAZOLE COMPOUNDS WHICH INHIBIT PLATELET AGGREGATION. | SMITHKLINE BEECHAM CORP (US) | 1996-09-25 | — | — | EP | disclosed |
| EP-0672034-A1 | BENZIMIDAZOLE COMPOUNDS WHICH INHIBIT PLATELET AGGREGATION | SMITHKLINE BEECHAM CORPORATION (US) | 1995-09-20 | — | — | EP | disclosed |
| WO-1994012478-A1 | BENZIMIDAZOLE COMPOUNDS WHICH INHIBIT PLATELET AGGREGATION | SMITHKLINE BEECHAM CORPORATION (US) | 1994-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160052890-A1 | COMPOUNDS USEFUL AS ANTIBIOTIC TOLERANCE INHIBITORS | CFTR, SLC11A2, MRPS18A | KDM4E 1749/4885ALDH1A1 2988/4885MAPT 4629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.